Table 3.

Evaluation of in vitro metabolic activity of human cells derived from colorectal carcinoma (CaCo-2) and human primary fibroblasts (MRC-5) treated with PLGA_OXA and PLGA_IO_OXA for 72 h determined by WST-1 assay. IC₅₀—concentration of the oxaliplatin (free—OXA, and in the nanoparticles) required to achieve 50 % reduction in cell viability; SD—standard deviation (from four replicates).

	IC50 ± SD [µg·mL−1] of the Oxaliplatin
Cell line	PLGA_OXA	PLGA_IO_OXA	OXA
CaCo-2	5.66 ± 0.24	12.44 ± 1.38	8.35 ± 0.48
MRC-5	11.66 ± 0.27	7.22 ± 0.69	14.30 ± 1.26